Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 162

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 162
---
 as well as selecting reliable suppliers.
NewGenIvf’s major suppliers are pharmaceutical companies.

Competition

NewGenIvf believes that it
is a long-standing provider of ARS in Asia Pacific that competes primarily based on the following competitive factors:

| ● | the value and comprehensiveness of the solutions; |

| ● | treatment that is effective and achieves desired outcomes; |

| ● | clients’ experience, including dedicated patient education, clinical guidance and emotional support; and |

| ● | access to a network of high-quality fertility specialists. |

NewGenIvf competes primarily
with other regional fertility service providers. While NewGenIvf does not believe any single competitor offers a comparably robust and
integrated fertility solution package as NewGenIvf in the regions that it operates, NewGenIvf’s competitors may compete in a variety
of ways, including by providing better services, having established local connections, fulfilling evolving client needs, as well as conducting
brand promotions and other marketing activities.

As NewGenIvf may introduce
new ancillary services and other companies may introduce similar fertility services as NewGenIvf’s, NewGenIvf may become subject
to additional competition.

Facilities

As of December 31, 2024, in
addition to its clinics, NewGenIvf leased one property in Hong Kong with an aggregate square footage of approximately 8,000 for its
administration support offices. NewGenIvf also operates its medical facilities as described above in “— Network of Facilities”
above. NewGenIvf believes that its existing facilities are suitable and adequate to meet its current needs.

<div align='center'>90

SELLING SECURITYHOLDERS</div>

This prospectus relates to
the possible resale from time to time by the Selling Securityholders of up to 50,000,000 Class A Ordinary Shares, which includes (i) up
to 20,000,000 Class A Ordinary Shares issuable by the Company to White Lion Capital, LLC (“White Lion”) in connection with
the Common Stock Purchase Agreement dated as of November 21, 2024, by and between the Company and White Lion (the “White Lion Purchase
Agreement”), and (ii) up to 30,000,000 Class A Ordinary Shares issuable upon the conversion of (a) the Remaining Additional Notes
(as defined below), (b) the senior convertible notes exchanged on August 8, 2024 (the “Exchange Notes”), (c) the